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Which calcium channel blockers achieve better renoprotection for aged
hypertensive population?Aged patients are the most rapidly growing population in devel-
oping chronic kidney disease (CKD) and end-stage renal disease
with a greater risk of cardiovascular (CV) morbidity and mortality.1
An ongoing clinical trial aims to investigate the efﬁcacy of calcium
channel blockers (CCBs), lercanidipine versus amlodipine, on renal
function in hypertensive patients aged at least 55 years (LEADER
Study).2 This study may solidify the rationale of selecting CCBs for
practical hypertension treatment guideline of elderly population
with CKD risks. The current study design still requires more consid-
eration relating to the issues about the interrelationships among
goals of blood pressure (BP) control, severity of renal damage, dia-
betes mellitus subpopulation, duration of follow-up, and comorbid
conditions.
Most current clinical guidelines recommend a lower BP target
of 130/80 mmHg or less for patients with CKD because of greater
risks of kidney failure and CV diseases.3 It is still debating between
BP target and CV and renal outcomes, especially in diabetes
mellitus subpopulation.4 A recent systematic review has demon-
strated that positive evidences favoring BP target of less than
125/75 mmHg to 130/80 mmHg for kidney failure were only found
in the subgroups with proteinuria greater than 1000 mg/d and
urinary protein/creatinine ratio greater than 0.22 g/g.5 Thus, it is
warranted to determine the rational BP target for aged population
based on additional measurements of urinary protein/creatinine
ratio and subgroups for diabetes. Another concern is whether it is
long enough to observe the change of renal biomarkers in a total
duration of 24-week follow-up.6
Moreover, CV disease and metabolic syndrome are signiﬁcant
risk factors for CKD.7,8 The confounding effects of these comorbid
diseases should be considered in evaluating the renoprotection
effect of CCBs.
CCBs have become a more suitable choice for antihypertensive
agents for aged hypertensive patients for their efﬁcacy and less
adverse effects of glucose intolerance, hyperuricemia, and postural
hypotension, as diuretics do.9 The results from LEADER study with
expanded protocols will provide promising evidence of prescribing2210-8335 Copyright  2011, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. P
doi:10.1016/j.jcgg.2011.06.001the appropriate CCBs as rational antihypertension treatment for
aged population with CKD and comorbidities.Jer-Chia Tsai, MD
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